AzTrials
AzTrials

Rheumatoid ArthritisPhase 3NCT00853385

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

A Phase 3 study testing CP 690,550, CP-690,550 and Biologic TNFi in people with Rheumatoid Arthritis, run by Pfizer at 125 sites in 21 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
CP 690,550, CP-690,550 and Biologic TNFi
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
717 participants
Where
125 sitesin 21 countries
Study dates
May 2009to Mar 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.
  • The patient must have had an inadequate response to methotrexate and have active disease, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) >28 mm in the local laboratory. 2. CRP >7 mg/L in the central laboratory.
  • No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
  • The patient must have been on a stable dose of 7.5 mg to 25 mg weekly of methotrexate and washed out of all other DMARDs.

Who cannot join

  • Blood dyscrasias including confirmed: 1. Hemoglobin <9 g/dL or Hematocrit <30%; 2. White blood cell count <3,000 cu.mm. Absolute neutrophil count <1,200 cu.mm; 4. Platelet count <100,000/L
  • History of any other autoimmune rheumatic disease other than Sjogren's syndrome
  • No malignancy or history of malignancy.
  • History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
  • Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism related adverse event.
  • Patients who have previously received adalimumab therapy for any reason.
  • Patients who are contraindicated for treatment with adalimumab in accordance with the approved local label.
  • Patients meeting the New York Heart Association Class III and Class IV Congestive Heart failure

Trial locations and contacts

125 sites in 21 countries.

125 sites in 21 countries

United States38 sites
  • Pfizer Investigational Site

    Austin, Texas, 78705

  • Pfizer Investigational Site

    Baton Rouge, Louisiana, 70809

  • Pfizer Investigational Site

    Boulder, Colorado, 80304

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45219

  • Pfizer Investigational Site

    Clarksburg, West Virginia, 26301

  • Pfizer Investigational Site

    Dallas, Texas, 75231

  • Pfizer Investigational Site

    Decatur, Georgia, 30033

  • Pfizer Investigational Site

    Evansville, Indiana, 47714

  • Pfizer Investigational Site

    Fair Oaks, California, 95628

  • Pfizer Investigational Site

    Gilbert, Arizona, 85234

  • Pfizer Investigational Site

    Glendale, Arizona, 85304

  • Pfizer Investigational Site

    Grand Rapids, Michigan, 49546

  • Pfizer Investigational Site

    Greenville, South Carolina, 29601

  • Pfizer Investigational Site

    Haverhill, Massachusetts, 01830

  • Pfizer Investigational Site

    Houston, Texas, 77034

  • Pfizer Investigational Site

    Jonesboro, Arkansas, 72401

  • Pfizer Investigational Site

    Largo, Florida, 33777

  • Pfizer Investigational Site

    Lexington, Kentucky, 40504

  • Pfizer Investigational Site

    Lexington, Kentucky, 40515

  • Pfizer Investigational Site

    Lubbock, Texas, 79424

  • Pfizer Investigational Site

    Marietta, Georgia, 30060

  • Pfizer Investigational Site

    Mesa, Arizona, 85202

  • Pfizer Investigational Site

    Mesquite, Texas, 75150

  • Pfizer Investigational Site

    Naples, Florida, 34102

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Pfizer Investigational Site

    Palm Harbor, Florida, 34684

  • Pfizer Investigational Site

    Paradise Valley, Arizona, 85253

  • Pfizer Investigational Site

    Phoenix, Arizona, 85037

  • Pfizer Investigational Site

    Pinellas Park, Florida, 33782

  • Pfizer Investigational Site

    Plantation, Florida, 33324

  • Pfizer Investigational Site

    Rockford, Illinois, 61107

  • Pfizer Investigational Site

    San Diego, California, 92108

  • Pfizer Investigational Site

    Seattle, Washington, 98104

  • Pfizer Investigational Site

    Seattle, Washington, 98122

  • Pfizer Investigational Site

    St. Petersburg, Florida, 33710

  • Pfizer Investigational Site

    Tampa, Florida, 33613

  • Pfizer Investigational Site

    Wichita, Kansas, 67203

  • Pfizer Investigational Site

    Worcester, Massachusetts, 01610

Other trials in United States

Czechia11 sites
  • Pfizer Investigational Site

    Brno, 60200

  • Pfizer Investigational Site

    Brno, 656 91

  • Pfizer Investigational Site

    Brno, 65691

  • Pfizer Investigational Site

    Brno-Židenice, 615 00

  • Pfizer Investigational Site

    Hlučín, 748 01

  • Pfizer Investigational Site

    Pardubice, 530 02

  • Pfizer Investigational Site

    Prague, 128 50

  • Pfizer Investigational Site

    Prague, 140 00

  • Pfizer Investigational Site

    Prague, 14800

  • Pfizer Investigational Site

    Praha 11 - Chodov, 148 00

  • Pfizer Investigational Site

    Zlín, 760 01

Other trials in Czechia

Canada8 sites
  • Pfizer Investigational Site

    London, Ontario, N6A 4V2

  • Pfizer Investigational Site

    Lunenburg, Nova Scotia, B0J 2C0

  • Pfizer Investigational Site

    Mississauga, Ontario, L5M 2V8

  • Pfizer Investigational Site

    Québec, Quebec, G1W 4R4

  • Pfizer Investigational Site

    Saskatoon, Saskatchewan, S7N 0W8

  • Pfizer Investigational Site

    Toronto, Ontario, M5T 2S8

  • Pfizer Investigational Site

    Trois-Rivières, Quebec, G8Z 1Y2

  • Pfizer Investigational Site

    Vancouver, British Columbia, V5Z 1L7

Other trials in Canada

Germany8 sites
  • Pfizer Investigational Site

    Aachen, 52064

  • Pfizer Investigational Site

    Berlin, 14059

  • Pfizer Investigational Site

    Frankfurt am Main, 60590

  • Pfizer Investigational Site

    Halle, 06108

  • Pfizer Investigational Site

    Halle, 06128

  • Pfizer Investigational Site

    Herne, 44652

  • Pfizer Investigational Site

    Ratingen, 40882

  • Pfizer Investigational Site

    Würzburg, 97080

Other trials in Germany

Poland7 sites
  • Pfizer Investigational Site

    Bialystok, 15-337

  • Pfizer Investigational Site

    Cieszyn, 43-400

  • Pfizer Investigational Site

    Kościan, 64-000

  • Pfizer Investigational Site

    Krakow, 31-501

  • Pfizer Investigational Site

    Sopot, 81-759

  • Pfizer Investigational Site

    Torun, 87-100

  • Pfizer Investigational Site

    Warsaw, 02-118

Other trials in Poland

Bulgaria6 sites
  • Pfizer Investigational Site

    Pleven, 5800

  • Pfizer Investigational Site

    Plovdiv, 4000

  • Pfizer Investigational Site

    Plovdiv, 4002

  • Pfizer Investigational Site

    Sevlievo, 5400

  • Pfizer Investigational Site

    Sofia, 1606

  • Pfizer Investigational Site

    Sofia, 1709

Other trials in Bulgaria

Slovakia6 sites
  • Pfizer Investigational Site

    Bratislava, 82606

  • Pfizer Investigational Site

    Dunajská Streda, 92901

  • Pfizer Investigational Site

    Košice, 040 01

  • Pfizer Investigational Site

    Nové Zámky, 94001

  • Pfizer Investigational Site

    Povazska Dystrica, 017 01

  • Pfizer Investigational Site

    Žilina, 010 01

Other trials in Slovakia

Spain6 sites
  • Pfizer Investigational Site

    A Coruña, A Coruña, 15006

  • Pfizer Investigational Site

    Madrid, Madrid, 28041

  • Pfizer Investigational Site

    Santiago de Compostela, A Coruña, 15705

  • Pfizer Investigational Site

    Seville, Sevilla, 41009

  • Pfizer Investigational Site

    Valencia, Valencia, 46026

  • Pfizer Investigational Site

    Vigo, Pontevedra, 36200

Other trials in Spain

Australia4 sites
  • Pfizer Investigational Site

    Cairns, Queensland, 4870

  • Pfizer Investigational Site

    Malvern East, Victoria, 3145

  • Pfizer Investigational Site

    Maroochydore, Queensland, 4558

  • Pfizer Investigational Site

    St Leonards, New South Wales, 2065

Other trials in Australia

Chile4 sites
  • Pfizer Investigational Site

    Providencia, Santiago, RM, 7530206

  • Pfizer Investigational Site

    Rancagua, Región del Libertador General Bernardo O’Higgins, 2841959

  • Pfizer Investigational Site

    Santiago, RM, 7510186

  • Pfizer Investigational Site

    Santiago, RM, 8360156

Other trials in Chile

Mexico4 sites
  • Pfizer Investigational Site

    Guadalajara, Jalisco, 44620

  • Pfizer Investigational Site

    Mexico City, Mexico City, 10700

  • Pfizer Investigational Site

    Morelia, Michoacán, 58249

  • Pfizer Investigational Site

    San Luis Potosí City, San Luis Potosí, 78240

Other trials in Mexico

South Korea4 sites
  • Pfizer Investigational Site

    Daegu, 705-718

  • Pfizer Investigational Site

    Gwangju, 501-757

  • Pfizer Investigational Site

    Seoul, 110-744

  • Pfizer Investigational Site

    Seoul, 133-792

Other trials in South Korea

Costa Rica3 sites
  • Pfizer Investigational Site

    Cartago, Cartago Province

  • Pfizer Investigational Site

    San José, Provincia de San José, 00

  • Pfizer Investigational Site

    San José, Provincia de San José

Other trials in Costa Rica

Croatia3 sites
  • Pfizer Investigational Site

    Osijek, 31000

  • Pfizer Investigational Site

    Split, 21000

  • Pfizer Investigational Site

    Zagreb, 10000

Other trials in Croatia

Philippines3 sites
  • Pfizer Investigational Site

    Angeles City, Pampanga, 2009

  • Pfizer Investigational Site

    Cebu City, 6000

  • Pfizer Investigational Site

    Lipa City, Batangas, 4217

Other trials in Philippines

United Kingdom3 sites
  • Pfizer Investigational Site

    Cannock, Staffs, WS11 2XY

  • Pfizer Investigational Site

    Dudley, West Midlands, DY1 2HQ

  • Pfizer Investigational Site

    Metropolitan Borough of Wirral, Merseyside, CH49 5PE

Other trials in United Kingdom

Denmark2 sites
  • Pfizer Investigational Site

    Frederiksberg, 2000

  • Pfizer Investigational Site

    Randers NOE, 8930

Other trials in Denmark

Thailand2 sites
  • Pfizer Investigational Site

    Amphoe Muang, Chiang Mai, 50200

  • Pfizer Investigational Site

    Rajathevee, Bangkok, 10400

Other trials in Thailand

Bosnia and Herzegovina1 site
  • Pfizer Investigational Site

    Sarajevo, 71000

Other trials in Bosnia and Herzegovina

Dominican Republic1 site
  • Pfizer Investigational Site

    Santo Domingo, Santo Domingo Province, 00000

Other trials in Dominican Republic

Finland1 site
  • Pfizer Investigational Site

    Hyvinkää, 05800

Other trials in Finland

About this study

Official title: Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.

Being tested
CP 690,550, CP-690,550, Placebo, Biologic TNFi
Keywords
oral DMARD, JAK inhibitor, clinical trial
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CP 690,550Drug

    tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months

  • CP-690,550Drug

    tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months

  • PlaceboOther

    placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months

  • PlaceboOther

    tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months

  • Biologic TNFiBiological

    Also called Humira (Adalimumab)

    placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months

Study groups in NCT00853385
Study groupRoleWhat they receive
5mgExperimentalNot described
Receives: Drug: CP 690,550
10 mgExperimentalNot described
Receives: Drug: CP-690,550
Placebo Sequence 1Placebo comparatorNot described
Receives: Other: Placebo
Placebo Sequence 2Placebo comparatorNot described
Receives: Other: Placebo
adalimumabActive comparatorNot described
Receives: Biological: Biologic TNFi

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6

    ACR20 response: greater than or equal to (>=) 20% improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

    Measured: Month 6

  2. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 3

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.

    Measured: Baseline, Month 3

  3. Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6

    DAS28-4 (ESR) calculated from SJC and TJC using 28-joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (<=) 3.2 implied low disease activity and > 3.2 to 5.1 implied moderate to high disease activity, and < 2.6 = remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

    Measured: Month 6

Secondary outcomes (42)
  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 1 and 3

    ACR20 response: >=20% improvement in TJC; >= 20% improvement in SJC; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Month 1, 3

  2. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 9 and 12

    ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Month 9, 12

  3. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 1, 3 and 6

    ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Month 1, 3, 6

  4. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 9 and 12

    ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Month 9, 12

  5. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 1, 3 and 6

    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Month 1, 3, 6

  6. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 9 and 12

    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Month 9, 12

  7. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6

    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6

  8. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9 and 12

    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Month 9, 12

  9. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6

  10. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9 and 12

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Month 9, 12

  11. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])

    DAS28-4 [CRP] calculated from SJC and TJC using 28 joint count, CRP (mg/L) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6, 9, 12

  12. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])

    DAS28-3 (ESR) was calculated from SJC and TJC using 28 joint count and ESR (mm/hour). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6, 9, 12

  13. Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 1, 3 and 6

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

    Measured: Month 1, 3, 6

  14. Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 9 and 12

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

    Measured: Month 9, 12

  15. Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6

    Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Baseline, Month 1, 3, 6

  16. Patient Assessment of Arthritis Pain at Month 9 and 12

    Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Month 9, 12

  17. Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3 and 6

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

    Measured: Baseline, Month 1, 3, 6

  18. Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

    Measured: Month 9, 12

  19. Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Month 1, 3 and 6

    Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Baseline, Month 1, 3, 6

  20. Physician Global Assessment (PGA) of Arthritis Pain at Month 9 and 12

    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Month 9, 12

  21. 36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.

    Measured: Baseline, Month 1, 3, 6

  22. 36-Item Short-Form Health Survey (SF-36) at Month 9 and 12

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.

    Measured: Month 9, 12

  23. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Baseline, Month 1, 3 and 6

    FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

    Measured: Baseline, Month 1, 3, 6

  24. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Month 12

    FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

    Measured: Month 12

  25. Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6

    Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Measured: Baseline, Month 1, 3, 6

  26. Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12

    Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Measured: Month 12

  27. Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

    Measured: Baseline, Month 1, 3, 6

  28. Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

    Measured: Month 12

  29. Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Baseline, Month 1, 3 and 6

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline, Month 1, 3, 6

  30. Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Month 12

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Month 12

  31. Work Limitations Questionnaire (WLQ) Score at Month 3 and 6

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).

    Measured: Month 3, 6

  32. Work Limitations Questionnaire (WLQ) Score at Baseline and Month 12

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).

    Measured: Baseline, Month 12

  33. Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6

    Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: any RA/non-RA related medical/non-medical (NM) practitioner visit, nursing home, hospital, surgery, emergency room (ER) treatment, diagnostic tests, over-night stay, home healthcare (HC) services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.

    Measured: Baseline, Month 3, 6

  34. Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12

    RA-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, NM practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, over-night stay, home HC services, and aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.

    Measured: Month 12

  35. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Baseline, Month 3, 6

  36. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Month 12

  37. Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Baseline, Month 3, 6

  38. Number of Days as Assessed Using RA-HCRU at Month 12

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Month 12

  39. Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.

    Measured: Baseline, Month 3, 6

  40. Number of Hours Per Day as Assessed RA-HCRU at Month 12

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.

    Measured: Month 12

  41. Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.

    Measured: Baseline, Month 3, 6

  42. Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12

    Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.

    Measured: Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionMar 2011
  4. Study completionMar 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
717 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00853385
Sponsor's protocol ID
A3921064
Status last verified
Jan 2013
First submitted
27 Feb 2009
Last updated
18 Jan 2013
Data monitoring committee
Yes

Publications

  • Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.

    PubMed 42888330
  • Strand V, Schulze-Koops H, Al-Emadi S, Kinch CD, Gruben D, Germino R, Connell CA, Mysler E. Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials. BMJ Open. 2025 Dec 24;15(12):e082366. doi: 10.1136/bmjopen-2023-082366.

    PubMed 41448717
  • Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.

    PubMed 39192350
  • Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.

    PubMed 38958913
  • Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials. Rheumatol Ther. 2024 Feb;11(1):35-50. doi: 10.1007/s40744-023-00612-7. Epub 2023 Nov 5.

    PubMed 37925660
  • Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.

    PubMed 37453736
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.

    PubMed 36814062
  • Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.

    PubMed 36601090
  • Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.

    PubMed 36600185
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Dikranian AH, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103.

    PubMed 35577477
  • Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Arthritis Res Ther. 2022 Apr 5;24(1):83. doi: 10.1186/s13075-022-02724-x.

    PubMed 35382883
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.

    PubMed 34921355
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.

    PubMed 34870800

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing CP 690,550, CP-690,550 and Biologic TNFi in people with Rheumatoid Arthritis, run by Pfizer at 125 sites in 21 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 125 sites in United States, Czechia, Canada, Germany, Poland and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 (time frame: Month 6). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00853385, which also lists 27 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2013; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in